Invasive Breast Carcinoma

About
Mappings

OncoTree: Invasive Breast Carcinoma (oncotree:BRCA)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (2) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Elacestrant
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
EMA (1) FDA (1) ER positive Invasive Breast Carcinoma Fulvestrant
FDA (1) PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (2) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (1) FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
FDA (1) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) FDA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Eribulin, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Margetuximab, Vinorelbine
FDA (1) HER2-positive Invasive Breast Carcinoma Neratinib
FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib
EMA (2) FDA (2) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (2) FDA (2) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
EMA (4) FDA (2) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (1) FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (1) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
EMA (1) FDA (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
EMA (2) FDA (1) HER2-positive Invasive Breast Carcinoma Trastuzumab
EMA (1) FDA (1) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) FDA (1) HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (3) HER2-positive Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (3) ERBB2 amplification Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Pembrolizumab
EMA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab emtansine
EMA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib
EMA (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) ER positive, ERBB2 amplification Invasive Breast Carcinoma Neratinib
EMA (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Neratinib
EMA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
EMA (1) ER positive, HER2-positive, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Capecitabine, Lapatinib
EMA (1) ER positive, ERBB2 amplification, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
EMA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (1) EGFR Exon 20 (Insertion) Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
EMA (1) ER positive, HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Imlunestrant
FDA (1) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan